315
Wakefield
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 26 / 27.5 / 94.6 / (61.8-138.6) / Male / 17 / 14.0 / 121.3 / (70.6-194.2)
Female / 11 / 11.3 / 97.5 / (48.6-174.4) / Female / 14 / 11.9 / 117.6 / (64.3-197.4)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 5.2 / nc / (nc-nc) / Male / 6 / 3.8 / 156.5 / (57.1-340.7)
Female / 4 / 4.8 / nc / (nc-nc) / Female / 1 / 3.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.8 / nc / (nc-nc) / Male / 20 / 13.8 / 144.9 / (88.5-223.8)
Female / 111 / 112.9 / 98.3 / (80.9-118.4) / Female / 13 / 13.9 / 93.8 / (49.9-160.4)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 10.4 / 48.0 / (15.5-112.1)
Female / 8 / 5.2 / 153.8 / (66.2-303.1) / Female / 2 / 5.5 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 33 / 42.4 / 77.9 / (53.6-109.4)
Female / 51 / 46.7 / 109.2 / (81.3-143.5) / Female / 14 / 11.6 / 120.6 / (65.9-202.4)
Esophagus / Pancreas
Male / 6 / 6.6 / 90.6 / (33.1-197.2) / Male / 11 / 7.9 / 139.8 / (69.7-250.1)
Female / 2 / 2.3 / nc / (nc-nc) / Female / 9 / 9.7 / 92.8 / (42.3-176.1)
Hodgkin Lymphoma / Prostate
Male / 2 / 2.3 / nc / (nc-nc) / Male / 124 / 110.7 / 112.0 / (93.2-133.5)
Female / 2 / 2.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 9 / 10.9 / 82.5 / (37.6-156.6) / Male / 3 / 7.2 / nc / (nc-nc)
Female / 5 / 7.8 / 63.9 / (20.6-149.1) / Female / 3 / 5.0 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 4.9 / nc / (nc-nc) / Male / 7 / 4.0 / 174.5 / (69.9-359.6)
Female / 1 / 1.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 12 / 8.4 / 142.5 / (73.6-249.0) / Male / 6 / 2.7 / 225.5 / (82.3-490.8)
Female / 10 / 7.8 / 129.0 / (61.8-237.3) / Female / 10 / 8.8 / 113.8 / (54.5-209.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 6 / 5.1 / 117.9 / (43.1-256.7)
Female / 2 / 2.2 / nc / (nc-nc) / Female / 22 / 21.9 / 100.5 / (62.9-152.1)
Lung and Bronchus / All Sites / Types
Male / 42 / 53.8 / 78.1 / (56.3-105.6) / Male / 370 / 366.4 / 101.0 / (90.9-111.8)
Female / 46 / 50.9 / 90.5 / (66.2-120.7) / Female / 367 / 375.1 / 97.8 / (88.1-108.4)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
316
Wales
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 1 / 1.3 / nc / (nc-nc) / Male / 2 / 0.8 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 5 / 6.3 / 78.7 / (25.4-183.8) / Female / 1 / 0.6 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.7 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 1 / 0.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 2 / 2.2 / nc / (nc-nc)
Female / 1 / 1.7 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.2 / nc / (nc-nc) / Male / 10 / 6.3 / 158.3 / (75.8-291.1)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.7 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 0.5 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 1.2 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 5 / 2.8 / 180.9 / (58.3-422.1) / Male / 23 / 20.2 / 113.7 / (72.1-170.6)
Female / 3 / 2.3 / nc / (nc-nc) / Female / 16 / 18.4 / 87.0 / (49.7-141.4)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
317
Walpole
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 19 / 24.9 / 76.3 / (45.9-119.2) / Male / 14 / 13.0 / 107.4 / (58.6-180.1)
Female / 6 / 8.8 / 67.8 / (24.8-147.6) / Female / 11 / 9.9 / 111.6 / (55.7-199.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 8 / 5.0 / 160.6 / (69.1-316.4) / Male / 1 / 3.5 / nc / (nc-nc)
Female / 6 / 4.0 / 150.4 / (54.9-327.3) / Female / 7 / 2.8 / 253.9 / (101.7-523.3)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.8 / nc / (nc-nc) / Male / 15 / 12.8 / 117.3 / (65.6-193.5)
Female / 113 / 94.7 / 119.3 / (98.3-143.5) / Female / 8 / 11.0 / 72.6 / (31.3-143.0)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 9.8 / 71.5 / (28.6-147.3)
Female / 4 / 4.4 / nc / (nc-nc) / Female / 8 / 4.5 / 176.5 / (76.0-347.7)
Colon / Rectum / Ovary
Male / 50 / 38.6 / 129.7 / (96.2-170.9)
Female / 31 / 35.7 / 86.8 / (59.0-123.2) / Female / 5 / 9.6 / 52.1 / (16.8-121.6)
Esophagus / Pancreas
Male / 6 / 6.1 / 98.0 / (35.8-213.2) / Male / 3 / 7.2 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 8 / 7.4 / 107.7 / (46.4-212.3)
Hodgkin Lymphoma / Prostate
Male / 1 / 2.2 / nc / (nc-nc) / Male / 107 / 102.9 / 104.0 / (85.2-125.7)
Female / 3 / 1.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 5 / 10.2 / 49.2 / (15.9-114.8) / Male / 9 / 6.6 / 137.2 / (62.6-260.4)
Female / 7 / 6.4 / 109.2 / (43.7-224.9) / Female / 3 / 3.8 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 4.6 / nc / (nc-nc) / Male / 2 / 3.9 / nc / (nc-nc)
Female / 3 / 1.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 6 / 7.8 / 77.0 / (28.1-167.7) / Male / 3 / 2.6 / nc / (nc-nc)
Female / 11 / 6.2 / 177.9 / (88.7-318.3) / Female / 10 / 7.5 / 134.1 / (64.2-246.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 4.7 / nc / (nc-nc)
Female / 1 / 1.7 / nc / (nc-nc) / Female / 15 / 18.7 / 80.3 / (44.9-132.4)
Lung and Bronchus / All Sites / Types
Male / 54 / 49.2 / 109.7 / (82.4-143.2) / Male / 347 / 338.1 / 102.6 / (92.1-114.0)
Female / 53 / 41.2 / 128.7 / (96.4-168.3) / Female / 343 / 304.6 / 112.6 / (101.0-125.2)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
318
Waltham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 56 / 56.7 / 98.8 / (74.6-128.3) / Male / 25 / 29.8 / 84.0 / (54.3-124.0)
Female / 16 / 22.8 / 70.1 / (40.0-113.8) / Female / 18 / 25.5 / 70.6 / (41.8-111.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 16 / 11.5 / 139.7 / (79.8-226.8) / Male / 9 / 7.9 / 114.1 / (52.1-216.7)
Female / 8 / 10.0 / 80.2 / (34.5-158.0) / Female / 12 / 7.1 / 168.6 / (87.0-294.6)
Breast / Non-Hodgkin Lymphoma
Male / 6 / 1.7 / 349.5 / (127.6-760.8) / Male / 28 / 29.5 / 95.0 / (63.1-137.3)
Female / 220 / 228.9 / 96.1 / (83.8-109.7) / Female / 22 / 28.5 / 77.2 / (48.4-116.9)
Cervix Uteri / Oral Cavity & Pharynx
Male / 28 / 21.4 / 130.8 / (86.9-189.1)
Female / 9 / 11.0 / 81.9 / (37.4-155.5) / Female / 8 / 11.4 / 70.2 / (30.2-138.4)
Colon / Rectum / Ovary
Male / 85 / 87.5 / 97.2 / (77.6-120.2)
Female / 92 / 93.5 / 98.4 / (79.3-120.7) / Female / 29 / 23.8 / 121.9 / (81.6-175.0)
Esophagus / Pancreas
Male / 16 / 13.6 / 117.3 / (67.0-190.6) / Male / 15 / 16.2 / 92.7 / (51.9-152.9)
Female / 4 / 4.6 / nc / (nc-nc) / Female / 17 / 19.5 / 87.4 / (50.9-139.9)
Hodgkin Lymphoma / Prostate
Male / 4 / 6.1 / nc / (nc-nc) / Male / 213 / 229.4 / 92.9 / (80.8-106.2)
Female / 5 / 5.1 / 98.1 / (31.6-229.0)
Kidney & Renal Pelvis / Stomach
Male / 10 / 22.5 / 44.5 / (21.3-81.8) / Male / 17 / 14.9 / 114.1 / (66.4-182.7)
Female / 13 / 16.0 / 81.3 / (43.2-139.0) / Female / 12 / 10.0 / 120.2 / (62.0-209.9)
Larynx / Testis
Male / 9 / 10.1 / 89.1 / (40.7-169.2) / Male / 8 / 11.5 / 69.8 / (30.1-137.5)
Female / 3 / 2.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 17 / 17.8 / 95.4 / (55.6-152.8) / Male / 6 / 6.1 / 97.6 / (35.6-212.4)
Female / 13 / 15.8 / 82.2 / (43.7-140.6) / Female / 19 / 19.8 / 96.2 / (57.9-150.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 8 / 10.4 / 76.9 / (33.1-151.5)
Female / 10 / 4.4 / 226.4 / (108.4-416.3) / Female / 38 / 45.2 / 84.1 / (59.5-115.4)
Lung and Bronchus / All Sites / Types
Male / 117 / 110.9 / 105.5 / (87.2-126.4) / Male / 762 / 765.9 / 99.5 / (92.6-106.8)
Female / 100 / 104.1 / 96.1 / (78.2-116.9) / Female / 732 / 766.4 / 95.5 / (88.7-102.7)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
319
Ware
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 12 / 10.5 / 114.5 / (59.1-200.0) / Male / 6 / 5.3 / 112.2 / (41.0-244.2)
Female / 6 / 4.3 / 139.7 / (51.0-304.1) / Female / 4 / 4.4 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 2.0 / nc / (nc-nc) / Male / 3 / 1.5 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 2 / 1.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 7 / 5.3 / 132.4 / (53.1-272.9)
Female / 25 / 42.2 / 59.3 / (38.4-87.5) / Female / 2 / 5.3 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 4.0 / nc / (nc-nc)
Female / 5 / 1.9 / 262.9 / (84.7-613.6) / Female / 3 / 2.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 17 / 16.2 / 105.2 / (61.2-168.4)
Female / 14 / 17.8 / 78.5 / (42.9-131.7) / Female / 2 / 4.4 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 2.5 / nc / (nc-nc) / Male / 2 / 3.0 / nc / (nc-nc)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 2 / 3.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.9 / nc / (nc-nc) / Male / 49 / 42.3 / 115.7 / (85.6-153.0)
Female / 0 / 0.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 4.2 / nc / (nc-nc) / Male / 1 / 2.8 / nc / (nc-nc)
Female / 2 / 3.0 / nc / (nc-nc) / Female / 2 / 1.9 / nc / (nc-nc)
Larynx / Testis
Male / 4 / 1.9 / nc / (nc-nc) / Male / 1 / 1.5 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 3.2 / nc / (nc-nc) / Male / 3 / 1.0 / nc / (nc-nc)
Female / 2 / 2.9 / nc / (nc-nc) / Female / 5 / 3.2 / 154.9 / (49.9-361.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.9 / nc / (nc-nc)
Female / 4 / 0.8 / nc / (nc-nc) / Female / 13 / 8.2 / 157.7 / (83.9-269.7)
Lung and Bronchus / All Sites / Types
Male / 28 / 20.6 / 136.2 / (90.5-196.9) / Male / 151 / 140.1 / 107.8 / (91.3-126.4)
Female / 20 / 19.4 / 103.0 / (62.9-159.1) / Female / 128 / 141.5 / 90.4 / (75.4-107.5)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
320
Wareham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 22 / 24.6 / 89.6 / (56.1-135.6) / Male / 14 / 12.0 / 116.7 / (63.7-195.8)
Female / 5 / 9.2 / 54.3 / (17.5-126.7) / Female / 8 / 9.7 / 82.8 / (35.7-163.2)
Brain and Other Nervous System / Multiple Myeloma
Male / 8 / 4.5 / 177.6 / (76.5-350.1) / Male / 2 / 3.4 / nc / (nc-nc)
Female / 7 / 3.9 / 178.6 / (71.6-368.1) / Female / 1 / 2.9 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.7 / nc / (nc-nc) / Male / 7 / 11.9 / 58.6 / (23.5-120.7)
Female / 89 / 93.1 / 95.6 / (76.8-117.6) / Female / 16 / 11.3 / 141.9 / (81.0-230.4)
Cervix Uteri / Oral Cavity & Pharynx
Male / 15 / 9.0 / 165.9 / (92.8-273.6)
Female / 6 / 4.2 / 144.4 / (52.7-314.2) / Female / 7 / 4.6 / 153.8 / (61.6-316.9)
Colon / Rectum / Ovary
Male / 49 / 37.7 / 129.9 / (96.1-171.7)
Female / 30 / 37.3 / 80.4 / (54.3-114.8) / Female / 8 / 9.5 / 84.0 / (36.2-165.5)
Esophagus / Pancreas
Male / 14 / 5.9 / 237.2 / (129.6-398.0) / Male / 6 / 7.0 / 85.7 / (31.3-186.6)
Female / 2 / 1.8 / nc / (nc-nc) / Female / 7 / 7.8 / 90.0 / (36.1-185.4)
Hodgkin Lymphoma / Prostate
Male / 1 / 1.8 / nc / (nc-nc) / Male / 135 / 100.6 / 134.2 / (112.5-158.9)
Female / 2 / 1.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 20 / 9.5 / 209.9 / (128.1-324.1) / Male / 6 / 6.4 / 93.8 / (34.2-204.1)
Female / 6 / 6.5 / 92.7 / (33.9-201.8) / Female / 7 / 3.9 / 178.8 / (71.6-368.4)
Larynx / Testis
Male / 5 / 4.4 / 114.7 / (37.0-267.7) / Male / 1 / 3.0 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 7 / 7.3 / 95.4 / (38.2-196.6) / Male / 2 / 2.2 / nc / (nc-nc)
Female / 7 / 6.2 / 113.0 / (45.3-232.8) / Female / 6 / 7.0 / 85.5 / (31.2-186.1)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 4 / 4.4 / nc / (nc-nc)
Female / 3 / 1.8 / nc / (nc-nc) / Female / 23 / 18.6 / 123.8 / (78.4-185.7)
Lung and Bronchus / All Sites / Types
Male / 72 / 48.1 / 149.7 / (117.2-188.6) / Male / 411 / 325.5 / 126.3 / (114.4-139.1)
Female / 69 / 42.6 / 162.0 / (126.1-205.1) / Female / 334 / 306.9 / 108.8 / (97.5-121.2)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
321
Warren
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 6 / 5.1 / 117.6 / (42.9-256.0) / Male / 2 / 2.6 / nc / (nc-nc)
Female / 0 / 1.7 / nc / (nc-nc) / Female / 3 / 2.0 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.0 / nc / (nc-nc) / Male / 1 / 0.7 / nc / (nc-nc)
Female / 1 / 0.8 / nc / (nc-nc) / Female / 1 / 0.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 2.6 / nc / (nc-nc)
Female / 13 / 18.7 / 69.4 / (36.9-118.6) / Female / 2 / 2.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 2.0 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 10 / 7.9 / 126.9 / (60.7-233.3)
Female / 11 / 7.0 / 156.6 / (78.1-280.2) / Female / 1 / 1.9 / nc / (nc-nc)
Esophagus / Pancreas
Male / 2 / 1.3 / nc / (nc-nc) / Male / 1 / 1.5 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 1 / 1.5 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.4 / nc / (nc-nc) / Male / 21 / 21.4 / 98.3 / (60.8-150.2)
Female / 1 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 2.1 / nc / (nc-nc) / Male / 3 / 1.3 / nc / (nc-nc)
Female / 2 / 1.3 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 0.9 / nc / (nc-nc) / Male / 3 / 0.7 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 1.6 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 3 / 1.2 / nc / (nc-nc) / Female / 1 / 1.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 1.0 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 4 / 3.7 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 4 / 10.1 / nc / (nc-nc) / Male / 63 / 69.2 / 91.0 / (69.9-116.5)
Female / 5 / 8.2 / 61.1 / (19.7-142.7) / Female / 59 / 60.5 / 97.5 / (74.2-125.8)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
322
Warwick
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 1 / 0.8 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 8 / 3.0 / 267.0 / (115.0-526.2) / Female / 0 / 0.3 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.3 / nc / (nc-nc)
Female / 1 / 1.0 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 4 / 3.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 2 / 1.6 / nc / (nc-nc) / Male / 7 / 11.2 / 62.6 / (25.1-129.1)
Female / 0 / 1.2 / nc / (nc-nc) / Female / 13 / 9.1 / 142.3 / (75.7-243.3)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
323
Washington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 1 / 0.6 / nc / (nc-nc) / Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 2 / 2.3 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.0 / nc / (nc-nc)
Female / 1 / 0.8 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.0 / nc / (nc-nc) / Male / 2 / 2.6 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 2 / 0.4 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 1.2 / nc / (nc-nc) / Male / 6 / 8.6 / 69.5 / (25.4-151.3)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 5 / 7.0 / 71.0 / (22.9-165.8)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
324
Watertown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 40 / 34.2 / 116.8 / (83.5-159.1) / Male / 13 / 17.2 / 75.4 / (40.1-128.9)
Female / 21 / 15.3 / 136.9 / (84.7-209.2) / Female / 14 / 16.4 / 85.3 / (46.6-143.1)
Brain and Other Nervous System / Multiple Myeloma
Male / 6 / 6.4 / 93.9 / (34.3-204.4) / Male / 3 / 4.7 / nc / (nc-nc)
Female / 11 / 6.3 / 173.3 / (86.4-310.2) / Female / 3 / 4.8 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 1.0 / nc / (nc-nc) / Male / 15 / 17.1 / 87.7 / (49.0-144.6)
Female / 139 / 147.0 / 94.6 / (79.5-111.7) / Female / 23 / 18.9 / 121.8 / (77.2-182.7)
Cervix Uteri / Oral Cavity & Pharynx
Male / 13 / 12.1 / 107.1 / (57.0-183.1)
Female / 1 / 7.1 / nc / (nc-nc) / Female / 9 / 7.4 / 121.8 / (55.6-231.3)
Colon / Rectum / Ovary
Male / 41 / 52.4 / 78.2 / (56.1-106.1)
Female / 58 / 63.8 / 90.9 / (69.0-117.6) / Female / 12 / 15.3 / 78.2 / (40.4-136.6)
Esophagus / Pancreas
Male / 8 / 8.0 / 100.3 / (43.2-197.7) / Male / 10 / 9.6 / 103.8 / (49.7-190.8)
Female / 4 / 3.1 / nc / (nc-nc) / Female / 12 / 13.3 / 90.2 / (46.6-157.6)
Hodgkin Lymphoma / Prostate
Male / 3 / 3.2 / nc / (nc-nc) / Male / 116 / 133.8 / 86.7 / (71.7-104.0)
Female / 5 / 3.0 / 164.5 / (53.0-384.0)
Kidney & Renal Pelvis / Stomach
Male / 15 / 13.0 / 115.1 / (64.4-189.9) / Male / 12 / 8.9 / 134.7 / (69.5-235.3)
Female / 7 / 10.4 / 67.1 / (26.9-138.3) / Female / 10 / 6.9 / 144.9 / (69.4-266.5)
Larynx / Testis
Male / 3 / 5.8 / nc / (nc-nc) / Male / 5 / 6.2 / 81.2 / (26.2-189.6)
Female / 4 / 1.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 8 / 10.4 / 77.2 / (33.3-152.2) / Male / 4 / 3.4 / nc / (nc-nc)
Female / 15 / 10.4 / 144.6 / (80.9-238.6) / Female / 16 / 12.5 / 128.2 / (73.3-208.3)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 7 / 6.1 / 115.7 / (46.3-238.3)
Female / 2 / 3.0 / nc / (nc-nc) / Female / 38 / 28.5 / 133.2 / (94.2-182.8)
Lung and Bronchus / All Sites / Types
Male / 64 / 66.3 / 96.6 / (74.4-123.3) / Male / 417 / 449.8 / 92.7 / (84.0-102.1)
Female / 64 / 68.5 / 93.5 / (72.0-119.4) / Female / 506 / 502.0 / 100.8 / (92.2-110.0)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
325
Wayland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 18 / 15.8 / 113.7 / (67.4-179.8) / Male / 13 / 8.0 / 161.9 / (86.1-276.9)
Female / 4 / 5.4 / nc / (nc-nc) / Female / 7 / 6.1 / 114.2 / (45.7-235.3)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 3.0 / nc / (nc-nc) / Male / 2 / 2.2 / nc / (nc-nc)
Female / 5 / 2.5 / 202.2 / (65.2-471.9) / Female / 2 / 1.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.5 / nc / (nc-nc) / Male / 12 / 7.9 / 152.7 / (78.8-266.7)
Female / 65 / 61.5 / 105.7 / (81.6-134.7) / Female / 5 / 6.7 / 74.2 / (23.9-173.2)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 6.3 / nc / (nc-nc)
Female / 1 / 2.7 / nc / (nc-nc) / Female / 1 / 2.9 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 21 / 24.5 / 85.6 / (53.0-130.8)
Female / 23 / 21.3 / 107.8 / (68.3-161.8) / Female / 10 / 6.1 / 163.3 / (78.2-300.3)
Esophagus / Pancreas
Male / 7 / 4.0 / 175.9 / (70.5-362.5) / Male / 3 / 4.6 / nc / (nc-nc)
Female / 3 / 1.1 / nc / (nc-nc) / Female / 4 / 4.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 5 / 1.1 / 451.1 / (145.4-1052.8) / Male / 78 / 68.1 / 114.6 / (90.6-143.0)
Female / 0 / 0.9 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 5 / 6.5 / 76.6 / (24.7-178.8) / Male / 3 / 4.1 / nc / (nc-nc)
Female / 3 / 4.0 / nc / (nc-nc) / Female / 2 / 2.2 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 3.0 / nc / (nc-nc) / Male / 1 / 1.7 / nc / (nc-nc)
Female / 1 / 0.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 4 / 4.8 / nc / (nc-nc) / Male / 2 / 1.5 / nc / (nc-nc)
Female / 4 / 3.7 / nc / (nc-nc) / Female / 7 / 4.5 / 154.1 / (61.8-317.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 3 / 3.0 / nc / (nc-nc)
Female / 1 / 1.0 / nc / (nc-nc) / Female / 15 / 12.3 / 121.7 / (68.0-200.7)
Lung and Bronchus / All Sites / Types
Male / 11 / 31.8 / 34.6 / (17.2-61.8) / Male / 208 / 216.0 / 96.3 / (83.6-110.3)
Female / 19 / 25.8 / 73.5 / (44.2-114.8) / Female / 195 / 190.9 / 102.1 / (88.3-117.5)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
326
Webster
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 24 / 19.6 / 122.6 / (78.5-182.4) / Male / 10 / 9.5 / 105.7 / (50.6-194.4)
Female / 12 / 8.0 / 150.7 / (77.8-263.3) / Female / 2 / 7.8 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 3.5 / nc / (nc-nc) / Male / 2 / 2.7 / nc / (nc-nc)
Female / 1 / 3.2 / nc / (nc-nc) / Female / 4 / 2.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.6 / nc / (nc-nc) / Male / 13 / 9.5 / 137.4 / (73.1-234.9)
Female / 75 / 74.1 / 101.3 / (79.6-126.9) / Female / 11 / 9.6 / 114.8 / (57.2-205.4)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 6.9 / 72.4 / (23.3-169.0)
Female / 3 / 3.3 / nc / (nc-nc) / Female / 6 / 3.7 / 161.1 / (58.8-350.6)
Colon / Rectum / Ovary
Male / 23 / 29.9 / 76.9 / (48.7-115.4)
Female / 33 / 33.5 / 98.6 / (67.8-138.4) / Female / 7 / 7.8 / 90.2 / (36.1-185.9)
Esophagus / Pancreas
Male / 5 / 4.5 / 109.9 / (35.4-256.6) / Male / 6 / 5.5 / 108.4 / (39.6-236.0)
Female / 2 / 1.6 / nc / (nc-nc) / Female / 8 / 7.0 / 115.0 / (49.5-226.6)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.5 / nc / (nc-nc) / Male / 71 / 75.5 / 94.1 / (73.5-118.7)
Female / 2 / 1.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 7.4 / 81.4 / (29.7-177.2) / Male / 8 / 5.1 / 155.8 / (67.1-306.9)
Female / 8 / 5.3 / 150.7 / (64.9-297.0) / Female / 3 / 3.6 / nc / (nc-nc)
Larynx / Testis
Male / 6 / 3.3 / 179.9 / (65.7-391.6) / Male / 4 / 2.5 / nc / (nc-nc)
Female / 2 / 0.9 / nc / (nc-nc)
Leukemia / Thyroid
Male / 5 / 5.8 / 85.5 / (27.6-199.5) / Male / 2 / 1.7 / nc / (nc-nc)
Female / 7 / 5.4 / 129.3 / (51.8-266.5) / Female / 2 / 5.5 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 3.4 / nc / (nc-nc)
Female / 1 / 1.6 / nc / (nc-nc) / Female / 18 / 14.5 / 124.4 / (73.7-196.6)
Lung and Bronchus / All Sites / Types
Male / 39 / 37.5 / 104.1 / (74.0-142.3) / Male / 249 / 252.9 / 98.5 / (86.6-111.5)
Female / 24 / 35.1 / 68.5 / (43.9-101.9) / Female / 254 / 255.0 / 99.6 / (87.7-112.6)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
327
Wellesley
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 19 / 29.5 / 64.3 / (38.7-100.5) / Male / 22 / 14.8 / 149.1 / (93.4-225.7)
Female / 14 / 11.3 / 123.4 / (67.4-207.1) / Female / 21 / 12.3 / 170.4 / (105.5-260.5)
Brain and Other Nervous System / Multiple Myeloma
Male / 5 / 5.5 / 90.3 / (29.1-210.7) / Male / 2 / 4.1 / nc / (nc-nc)
Female / 2 / 5.1 / nc / (nc-nc) / Female / 1 / 3.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.9 / nc / (nc-nc) / Male / 14 / 14.6 / 96.0 / (52.4-161.1)
Female / 124 / 118.2 / 104.9 / (87.3-125.1) / Female / 11 / 14.0 / 78.6 / (39.2-140.6)
Cervix Uteri / Oral Cavity & Pharynx
Male / 10 / 11.4 / 87.8 / (42.0-161.5)
Female / 2 / 5.2 / nc / (nc-nc) / Female / 3 / 5.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 43 / 45.6 / 94.3 / (68.2-127.0)
Female / 34 / 46.2 / 73.6 / (51.0-102.8) / Female / 8 / 12.1 / 65.9 / (28.4-129.9)
Esophagus / Pancreas
Male / 7 / 7.2 / 96.6 / (38.7-199.0) / Male / 4 / 8.5 / nc / (nc-nc)
Female / 5 / 2.3 / 219.7 / (70.8-512.8) / Female / 9 / 9.6 / 93.9 / (42.9-178.3)
Hodgkin Lymphoma / Prostate
Male / 4 / 2.2 / nc / (nc-nc) / Male / 124 / 122.5 / 101.2 / (84.2-120.7)
Female / 1 / 2.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 8 / 11.8 / 67.6 / (29.1-133.2) / Male / 3 / 7.8 / nc / (nc-nc)
Female / 10 / 8.1 / 123.8 / (59.3-227.7) / Female / 3 / 4.9 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 5.4 / nc / (nc-nc) / Male / 0 / 3.3 / nc / (nc-nc)
Female / 2 / 1.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 9 / 9.0 / 100.4 / (45.8-190.6) / Male / 3 / 2.7 / nc / (nc-nc)
Female / 5 / 8.0 / 62.8 / (20.2-146.5) / Female / 6 / 9.2 / 65.4 / (23.9-142.3)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 4 / 5.5 / nc / (nc-nc)
Female / 2 / 2.2 / nc / (nc-nc) / Female / 20 / 23.5 / 85.0 / (51.9-131.3)
Lung and Bronchus / All Sites / Types
Male / 29 / 58.1 / 49.9 / (33.4-71.7) / Male / 326 / 395.9 / 82.3 / (73.6-91.8)
Female / 29 / 52.0 / 55.8 / (37.4-80.2) / Female / 337 / 385.5 / 87.4 / (78.3-97.3)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
328
Wellfleet
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 6 / 4.8 / 126.0 / (46.0-274.3) / Male / 2 / 2.1 / nc / (nc-nc)
Female / 3 / 1.6 / nc / (nc-nc) / Female / 2 / 1.5 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 0.7 / nc / (nc-nc) / Male / 1 / 0.6 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.1 / nc / (nc-nc) / Male / 1 / 2.2 / nc / (nc-nc)
Female / 16 / 15.8 / 101.2 / (57.8-164.3) / Female / 2 / 1.9 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 1.6 / nc / (nc-nc)
Female / 4 / 0.6 / nc / (nc-nc) / Female / 1 / 0.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 5 / 7.2 / 69.2 / (22.3-161.5)
Female / 8 / 6.3 / 126.3 / (54.4-248.9) / Female / 0 / 1.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 1.1 / nc / (nc-nc) / Male / 3 / 1.3 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 1 / 1.3 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.3 / nc / (nc-nc) / Male / 24 / 18.4 / 130.3 / (83.5-193.9)
Female / 0 / 0.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 1.7 / nc / (nc-nc) / Male / 1 / 1.2 / nc / (nc-nc)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 0.8 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 1.3 / nc / (nc-nc) / Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc) / Female / 0 / 1.0 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.8 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 2 / 3.2 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 5 / 9.1 / 55.0 / (17.7-128.3) / Male / 69 / 60.0 / 114.9 / (89.4-145.5)
Female / 9 / 7.4 / 121.5 / (55.4-230.6) / Female / 55 / 51.8 / 106.2 / (80.0-138.2)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
329
Wendell
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002
Bladder, Urinary / Melanoma of Skin
Male / 0 / 0.8 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 1 / 0.5 / nc / (nc-nc)
Female / 3 / 3.6 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.2 / nc / (nc-nc)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 3.4 / nc / (nc-nc)
Female / 1 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 0.4 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 1.5 / nc / (nc-nc) / Male / 3 / 11.4 / nc / (nc-nc)
Female / 0 / 1.1 / nc / (nc-nc) / Female / 7 / 9.9 / 70.9 / (28.4-146.1)
- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;
330